EG-101
Phase 1Small molecule
EG-101 is one of 7 small molecule programs targeting Severe Pre-Eclampsia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Severe Pre-Eclampsia
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Epsom Salt
FFresenius Kabi Oncology Ltd.
Approved
Normodyne
AAlvogen Korea
Approved
Lanoxin
AAdvanz Pharma
Approved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
EG-101
EEvergreen Therapeutics, Inc.
Phase 1
Magnesium Sulfate Administration
UUniversity of California, San Francisco
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EG-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- EEvergreen Therapeutics, Inc.